Every cell in the body uses glucose for energy including cancer cells, brain cells, muscle cells, and gut lining. Cancer cells consume glucose faster because they divide rapidly, a phenomenon called the Warburg effect discovered nearly a hundred years ago. Cutting sugar completely from diet won’t starve a tumor because the liver manufactures glucose from protein and fat through gluconeogenesis even when dietary sugar drops to zero.

According to Dr. Sandeep Nayak, Best cancer treatment in Bangalore,
“Families ban sweets from the patient’s plate thinking they’re starving the cancer. They’re starving the patient instead. Body makes its own glucose regardless. Cancer doesn’t care whether the sugar came from gulab jamun or from your own muscle breaking down.”

Myth came from a real observation stretched into a wrong conclusion. Cancer cells do use more glucose. True. Stopping sugar intake stops cancer growth. False. Big difference.

• Warburg effect: Cancer cells burn glucose faster because rapid division needs rapid fuel. PET scans use radioactive glucose that tumors absorb more, lighting up on the image. People saw those bright spots and assumed sugar causes growth. It doesn’t. It just shows where cells are dividing fast.
• Body makes its own: Zero-sugar diet and your liver still converts protein and fat into glucose. Every cell gets fed regardless of what you ate for lunch. You can’t selectively cut off supply to cancer without cutting off your brain and immune system first.
• No direct link: No published human study shows dietary sugar directly speeds up tumor growth. Connection runs through obesity and insulin resistance not through some direct pipeline from your chai to the tumor.
• Dangerous restriction: Cancer patients who cut all carbs lose muscle, weaken immunity, tolerate chemo badly. Malnourished patient on chemo does worse than well-fed one every single time. Any oncology dietitian will tell you this within five minutes of meeting you.

Your oncologist coordinates nutrition planning that balances healthy eating with adequate calories during treatment instead of fear-based food bans.

Sugar doesn’t directly feed tumors but too much of it over years creates body conditions where cancer develops more easily. That’s the real story, not the WhatsApp version.

• Obesity: High sugar diets cause weight gain. Excess fat raises risk for 13 cancer types including breast, colon, pancreatic. Fat tissue pumps out hormones and inflammatory signals that make the neighbourhood friendlier for cancer cells. That’s the actual sugar-cancer link, not glucose travelling directly to a tumor.
• Insulin resistance: Years of excess sugar keeps insulin levels chronically high. High insulin acts like a growth signal for certain cancers. This plays out over decades not overnight from one mithai box at Diwali. Moderation matters, panic doesn’t.
• Inflammation: Processed sugar triggers chronic low-grade inflammation. Sustained inflammation damages DNA over time raising mutation rates. Whole fruits with natural sugars don’t do this because fibre slows absorption and prevents the insulin spike that processed sugar creates.
• What to actually do: Cut processed sugar and sugary drinks. Eat whole fruits not fruit juice. Keep weight in check. But during cancer treatment don’t eliminate carbs entirely because your body and your chemo both need that energy to work properly.

Understanding how cancer myths travel through families explains why the sugar story persists, fear amplifies oversimplifications far beyond what the actual science supports.

Dr. Sandeep Nayak’s team at MACS Clinic includes a dietitian who builds nutrition plans based on treatment protocol and calorie needs not on WhatsApp forwards about sugar or turmeric or alkaline water curing cancer.

Patient gets told what to eat and why with reasoning behind it. Not a photocopied diet sheet from 2010 saying avoid sugar in bold without explaining what that means for someone whose body is fighting cancer and chemo at the same time.

Reference Links-

1. Sugar and cancer myths — National Cancer Institute
2. Diet and cancer risk — World Health Organization

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Refusing chemo when your oncologist recommended it after surgery means microscopic cancer cells already in your blood or lymph nodes stay alive with nothing to stop them. Adjuvant chemo exists to kill exactly those cells surgery couldn’t reach. Skipping it raises recurrence risk by 30-50% depending on cancer type and stage.

According to Dr. Sandeep Nayak, Best cancer treatment in Bangalore,
“They refuse because someone’s neighbour had a bad time on chemo. Meanwhile cells surgery missed are doubling every few weeks while the patient reads miracle cure articles on WhatsApp instead of reading their own pathology report.”

Chemo gets recommended when your pathology report shows specific risk factors. Not because a protocol says so.

• Recurrence: Cells floating in blood or parked in tiny nodes grow back silently over months. Show up later as liver or lung mets when the original was Stage II and that stage jump is what skipping chemo gambles on.
• Distant spread: Once cancer reaches bones, brain, liver the goal shifts from cure to control permanently. Chemo would’ve addressed those circulating cells before they had a chance to settle somewhere new and set up shop.
• Survival gap: Breast, colon, ovarian data consistently shows 15-25% survival difference between patients who finished adjuvant chemo and those who walked away. That gap direction never flips regardless of which journal you check.
• Harder drugs later: Cancer returning after skipped first-line chemo needs more aggressive regimens with worse side effects. What your oncologist offered initially was actually the gentler version. What comes next hits harder every time around.

Your oncologist explains exactly why chemo landed on your treatment plan through precision oncology pathology review specific to your report.

Some patients genuinely don’t need it. Good oncologist says that before you even bring it up.

• Very early stage: Stage I, clean margins, no nodes, favourable biology. Oncologist not recommending chemo means declining something that wasn’t offered in the first place. That’s following the plan not refusing treatment.
• Elderly unfit patients: 82-year-old with bad kidneys and weak heart may not survive chemo well enough to gain anything from it. Toxicity outweighing benefit is real clinical math not a loophole to skip treatment.
• Genomic testing: Oncotype DX for breast cancer scores whether chemo actually moves the needle for your specific tumor or not. Low score means chemo adds nothing measurable and skipping it then is data talking not fear.
• Comfort priority: Advanced cancer where cure already left the table. Choosing fewer hospital visits and better remaining months over IV drips that won’t meaningfully extend life is a medical call not surrender.

Knowing how targeted therapy works as an alternative helps patients understand that refusing chemo doesn’t always mean refusing all systemic treatment when better-matched options exist for their tumor.

Dr. Sandeep Nayak’s team at MACS Clinic explains your pathology in language you actually follow. Decision stays yours but it’s built on your report numbers not internet panic or someone’s cousin’s experience from ten years ago.

Patient needing chemo hears why with their own data sitting on the table. Patient not needing it hears that too. Difference between pushing treatment and explaining it properly is what makes consent real instead of a formality.

Reference Links-

1. Adjuvant chemotherapy guidelines — National Cancer Institute
2. Cancer treatment decision-making — World Health Organization

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Breast reconstruction after mastectomy uses either implant-based reconstruction with silicone or saline devices placed under the chest muscle, or autologous flap reconstruction using the patient’s own tissue from the abdomen, back or thighs. Implants offer shorter surgery, faster recovery and no donor site scarring but feel firmer and may need replacing over time. Flap techniques create natural-feeling breasts that age with the body and handle post-mastectomy radiation far better than any implant can.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Reconstruction is part of the surgical plan from the start, not an afterthought. Getting the right method for that specific patient depends on the oncological plan and the patient’s body together.”

Implant reconstruction is the faster, less complex option and works well in the right clinical situation.

• How It Works: A silicone or saline implant is placed under the chest muscle either immediately at mastectomy or staged using a tissue expander first that gradually stretches the skin before the final implant is inserted weeks later.
• Shorter Recovery: No donor site means faster overall recovery than flap procedures and most patients are discharged sooner and return to daily activity more quickly than those having tissue transferred from elsewhere on the body.
• Radiation Makes It Unsuitable: Post-mastectomy radiation significantly increases implant complication rates including capsular contracture and device failure and breast cancer treatment centres typically recommend flap reconstruction for patients who need chest wall radiation after mastectomy.
• Long-Term Considerations: Implants may need replacement over time and don’t age the same way natural tissue does while flap reconstruction using the patient’s own tissue behaves more naturally as the body changes with age and weight over years.

Implant reconstruction is the most common first choice where radiation isn’t anticipated and the patient’s anatomy supports it without requiring complex donor site surgery.

• Flap Reconstruction Handles Radiation Better: Tissue transferred from the patient’s own body tolerates radiation far better than a synthetic implant and for Stage 3 patients needing post-mastectomy chest wall radiation, flap options produce significantly more predictable long-term results.
• DIEP and TRAM Flaps Use Abdominal Tissue: These procedures harvest tissue from the lower abdomen creating a natural-feeling breast while simultaneously flattening the donor area, which some patients find a welcome additional outcome alongside the reconstruction itself.
• Latissimus Flap Uses Back Tissue: Tissue from the back combined with a small implant underneath is used when abdominal tissue isn’t suitable and robotic cancer surgery centres increasingly perform these with minimally invasive donor site techniques to reduce back scarring and recovery time.
• Staged vs Immediate Timing: Both approaches can be done immediately at mastectomy or delayed until after chemotherapy and radiation are complete with timing planned around the oncological treatment sequence rather than reconstruction preference alone.

Reconstruction type and timing are decided together with the surgical oncology team before mastectomy happens and for more on the latissimus flap technique specifically, our blog on latissimus dorsi covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to every mastectomy including full reconstruction planning from the start of the surgical discussion. He heads Oncology Services across Karnataka and leads breast cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT and over 25 published clinical studies. Patients who want reconstruction discussed as part of their mastectomy plan rather than separately are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Breast Reconstruction After Mastectomy
2. World Health Organization — Breast Cancer Treatment

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Small operable tumours go straight to surgery. Large, locally advanced or biologically aggressive breast cancers receive chemotherapy first to shrink the disease before the surgeon operates. The decision is made at tumour board using staging results, biopsy findings and receptor status together before any treatment begins.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“The sequence isn’t a preference it’s a clinical decision made from staging, tumour biology and what gives that specific patient the best surgical and systemic outcome together.”

Surgery opens the treatment plan when the tumour is directly resectable and operating immediately gives the clearest oncological result for that patient.

• Small Operable Tumour: When the tumour is contained, clear margins are achievable without prior chemotherapy and operating straight away removes the cancer while it’s still in its most favourable surgical state.
• Pathology Guides Everything After: The surgical specimen gives the team actual margin status, nodal count and receptor confirmation from real tissue rather than imaging estimates and breast cancer treatment planning for adjuvant chemotherapy becomes more precise as a result.
• Hormone Positive Low-Grade Cancer: These tumours respond modestly to chemotherapy compared to HER2 positive or triple negative subtypes making chemotherapy before surgery less valuable and surgery first the more efficient clinical pathway.
• No Benefit to Delay: For operable early breast cancer there’s no oncological benefit to running chemotherapy before an operation that can be safely and effectively performed right now so the tumour board recommends surgery without delay.

Surgery first is standard for early operable breast cancer where the disease is contained and the operation can deliver complete tumour clearance without prior systemic treatment.

• Chemo First Shrinks What the Surgeon Has to Deal With: When the tumour is large or has spread to multiple nodes running chemotherapy first reduces the operative complexity and in some cases turns a mastectomy case into one where lumpectomy becomes achievable after good response.
• Response Itself Is Valuable Information: How the tumour behaves during chemotherapy tells the team something that no pre-treatment imaging can: if the cancer disappears completely that result carries significant prognostic weight and shapes every decision that follows.
• HER2 Positive and Triple Negative Go First to Chemo: Both subtypes respond dramatically to neoadjuvant regimens and complete pathological response rates in these groups are high enough that running chemotherapy first is now the clinical standard rather than the exception.
• The Specimen After Chemo Guides What Comes Next: The surgical pathology after neoadjuvant chemotherapy shows whether cancer was eliminated completely or partially and that result determines what adjuvant treatment and robotic cancer surgery or conventional follow-up operation is still needed.

The sequence is planned at diagnosis but adjusted at every decision point based on actual clinical findings and for more on how complex surgical treatment decisions are made, our blog on cytoreductive surgery covers detailed surgical planning in context.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to every breast cancer sequencing decision including neoadjuvant coordination and surgical timing. He heads Oncology Services across Karnataka and leads breast cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT and over 25 published clinical studies. Patients wanting clarity on why their treatment is sequenced a specific way are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Breast Cancer Treatment
2. World Health Organization — Breast Cancer Treatment

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Two different specialists with two completely different roles. A surgical oncologist operates to remove tumours. A medical oncologist prescribes chemotherapy, targeted therapy and immunotherapy. Most cancer patients need both at some point and who sees you first depends on the cancer type, how advanced it is and what the tumour board decides should happen before anything else.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “patients often arrive not knowing which specialist is running their care and the honest answer is that both are involved the question is who goes first and why, not which one matters more.”

The roles are clinically distinct even though both carry the oncologist title. Here is a clear breakdown.

• Operable Cancers See Surgery First: When a tumour appears directly resectable at diagnosis the surgical oncologist typically sees the patient first and for early breast cancer treatment this means a surgical assessment before chemotherapy enters the conversation at all.
• Advanced Cancers See Medical Oncology First: Locally advanced or metastatic presentations often go to the medical oncologist first because systemic treatment needs to run before surgery becomes technically possible or clinically appropriate for that specific patient.
• Neither Overrides the Other: Both contribute to the same tumour board discussion before any treatment plan is confirmed and the patient is told clearly which specialist is leading which phase of their treatment.
• Both Are Always Involved: Even when surgery comes first, the medical oncologist is already planning what adjuvant treatment follows and when the surgical team will be needed again if disease recurs or restaging changes the plan.

The sequence is decided by the tumour board based on the clinical picture rather than by either specialist acting independently.

The collaboration between surgical and medical oncology isn’t a one-time referral it happens repeatedly throughout a full cancer treatment course.

• Before Surgery in Locally Advanced Cases: The medical oncologist runs neoadjuvant chemotherapy first to shrink the tumour before the surgical team operates while surgical input on the operative plan runs in parallel from the start of the treatment discussion.
• After Surgery for Adjuvant Planning: Once pathology confirms margin and nodal status the medical oncologist plans adjuvant chemotherapy using the staging information that robotic cancer surgery or conventional surgery provides from the specimen.
• Tumour Board Keeps Both Aligned: High-volume cancer centres hold weekly tumour board meetings where both specialists review the same case simultaneously and agree on the sequence before either starts treatment rather than working from separate referral letters.
• When Surgery Isn’t the Plan: Some cancers are managed entirely without surgery in which case the medical oncologist leads throughout while the surgical oncologist’s assessment of operability after systemic response remains part of the ongoing clinical conversation.

The two roles run in parallel rather than in sequence and for more on what cancer surgery involves within this framework, our blog on cancer surgery covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to cancer cases requiring coordinated surgical and medical oncology input across all cancer types. He heads Oncology Services across Karnataka and leads cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients wanting clarity on who they should see first and in what order are assessed here with every decision going through full tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Cancer Treatment Team
2. National Institutes of Health — Surgical vs Medical Oncology

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.